Our Impact | CLL Global Research Foundation


CLL Global Research Foundation was founded by patients and families who refused to wait for progress. Twenty years later, the treatment of chronic lymphocytic leukemia (CLL) has been transformed, and CLL Global–funded researchers helped make it happen.

Researchers from around the world at the CLL Global Alliance Meeting.
Researchers from around the world at the CLL Global Alliance Meeting.

CLL Global by the Numbers (2005–2026)

  • $47M+ invested in CLL research.
  • ~40 institutions in 12 countries.
  • Nearly 300 scientific publications.
  • Nearly every FDA-approved CLL therapy was advanced by research CLL Global funded.

 

From the Lab to Patients

Our founder, Dr. Michael Keating of UT MD Anderson Cancer Center, developed FCR, the first CLL treatment shown to help patients live longer. CLL Global–funded follow-up studies showed that some patients treated with FCR more than a decade ago remain in remission today.

Since then, CLL Global has funded laboratory, translational and clinical research on the therapies that have changed CLL care:

Therapy

What it is

First approved for CLL

FCR

Chemoimmunotherapy developed by our founder

2010

Obinutuzumab

Antibody therapy

2013

Ibrutinib

Oral BTK inhibitor

2014

Idelalisib

Oral PI3K inhibitor

2014

Venetoclax

Oral BCL-2 inhibitor

2016

Acalabrutinib

Oral BTK inhibitor

2019

Zanubrutinib

Oral BTK inhibitor

2023

Pirtobrutinib

Next-generation BTK inhibitor

2023

Liso-cel

CAR T-cell therapy

2024

 

A Closer Look: Treatment With a Finish Line

CLL Global funded Dr. Nitin Jain’s trial at UT MD Anderson of ibrutinib plus venetoclax as a first treatment for CLL, published in the New England Journal of Medicine. This all-oral combination is given for a fixed period, so many patients can finish treatment and stop taking medication rather than taking it indefinitely.

What Your Gift Funds Next

The work isn’t finished. Today, CLL Global focuses on the greatest remaining needs of patients:

  • Restoring the immune system so people with CLL can fight infections, respond to vaccines and benefit from immune-based treatments such as CAR T-cell therapy.
  • Understanding how CLL begins so it can be detected earlier, doctors can predict who will need treatment and, one day, CLL can be prevented.
  • New treatments when current drugs stop working, for patients whose disease has become resistant to BTK and BCL-2 inhibitors.
  • Richter transformation and high-risk CLL: better outcomes for patients facing the most aggressive forms of the disease.
 

Why CLL Global?

  • We fund ideas early. We support high-impact projects that are often hard to fund elsewhere, so promising ideas move from the lab to patients faster and go on to attract larger funding.
  • We bring the best minds together. Our CLL Global Alliance connects leading laboratories around the world to share ideas, samples and data.
  • We keep patients at the center. Through our virtual town halls and Patient-Focused Research Symposium, the researchers we fund share their progress directly with patients and families.
 

Be Part of the Next Breakthrough

Every CLL treatment approved today started as an idea that needed early funding. Your gift helps bring the next breakthrough to patients sooner.

Give Today

Many employers match charitable gifts. Ask yours whether your donation can be doubled.

CLL Global Research Foundation is a 501(c)(3) public charity. Contributions are tax-deductible.